The Effects of Thymoquinone and β-aminoisobutyric Acid on Brain Tissue of Streptozotocin-Induced Diabetic Rats
2021
Aktas, Ibrahim | Gur, Fatih Mehmet
The aim of this study is to investigate the effects of timoquinone and β-aminoisobutyric acid (BAIBA) on the brain tissue of streptozotocin-induced diabetic rats. Randomly selected 35 male rats were divided into five groups of 7 animals each at 8 weeks. The groups are respectively; C, D, DT, DB, DTB. Diabetes mellitus (DM) was induced by intraperitoneally injection of a single dose of streptozotocin. Thymoquinone (20 mg/kg/day) and BAIBA (100 mg/kg/day) were administered to diabetic rats by gavage for 5 weeks. In the D group; glutathione (GSH) levels decreased. Again, in this group; relative brain weight, malondialdehyde (MDA), glucose, cholesterol (CH) triglyceride (TG) and creatine kinase BB (CK BB) levels increased. The histological structure of the hippocampus, cortex and cerebellum in diabetic rats was similar to that of the other groups. No histopathological alterations were detected in the central nervous system (CNS) at light microscopic level in any of the groups. It was observed that these biocehemical changes occurring after DM were reversed significantly in DT, DB and DBT groups. Although the protective effects of BAIBA were stronger than thymoquinone, the most effective result was obtained with the combined use of thymoquinone+BAIBA. The biochemical results obtained in this study showed that oxidative stress occurred in the brain tissue of diabetic rats. However, the effects of oxidative stress on the histological structure of brain tissue could not be detected by light microscopic level. The biochemical analysis results suggested that administration thymoquinone and BAIBA could be used as therapeutic agents with the potential to ameliorate brain damage caused by diabetes mellitus because of the antioxidant effects.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Anatolia Academy of Sciences Ltd.
